Engineered lentivector targeting of dendritic cells for in vivo immunization. - sprookjes - yvandenbroek - TriplyDB

Engineered lentivector targeting of dendritic cells for in vivo immunization.

Engineered lentivector targeting of dendritic cells for in vivo immunization.

http://www.wikidata.org/entity/Q36629181

about

Recent Advances in Lentiviral Vaccines for HIV-1 Infection Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines Trial watch: Dendritic cell-based anticancer therapy Lentiviral vector delivery of human interleukin-7 (hIL-7) to human immune system (HIS) mice expands T lymphocyte populations Visualization of DC-SIGN-mediated entry pathway of engineered lentiviral vectors in target cells Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts.Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity.Polymeric Materials for Gene Delivery and DNA Vaccination Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.Recombinant vesicular stomatitis virus transduction of dendritic cells enhances their ability to prime innate and adaptive antitumor immunity.Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy Dendritic cell-based human immunodeficiency virus vaccine.Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo Virus-receptor mediated transduction of dendritic cells by lentiviruses enveloped with glycoproteins derived from Semliki Forest virus Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity.In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.Dendritic cell-directed vaccination with a lentivector encoding PSCA for prostate cancer in mice Immunization delivered by lentiviral vectors for cancer and infectious diseases.Lentiviral vectors, two decades later.Production of lentiviral vectors with enhanced efficiency to target dendritic cells by attenuating mannosidase activity of mammalian cells.The inside out of lentiviral vectors Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo Preferential lentiviral targeting of astrocytes in the central nervous system.Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.Classification of current anticancer immunotherapies Homeostatic cytokines orchestrate the segregation of CD4 and CD8 memory T-cell reservoirs in mice.Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells.Enhanced survival and engraftment of transplanted stem cells using growth factor sequestering hydrogels.Construction of stable producer cells to make high-titer lentiviral vectors for dendritic cell-based vaccination.A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells.Microparticle surface modifications targeting dendritic cells for non-activating applications.miR-146a controls the resolution of T cell responses in mice.

P2860

Q26742169-11E51BDD-E85E-4109-9053-9001EDC4B9B7 Q27013679-60FA629A-D8F5-46CE-B582-317478E82811 Q27024047-513ACE5F-46E9-46FD-AFC6-BF88E80DFFB8 Q27322228-3191DC6C-3A6D-46CE-B01A-45BED079A11A Q28534404-AA7E85D4-6AF9-4F00-92A5-DE4764266C60 Q30493686-2069787B-87BB-4203-BC55-6A3706FF08EB Q33564383-7E9C4921-2901-459E-89EC-DC07BC2BD991 Q33565296-E7B51FA2-A2B6-4FB3-9EA9-28FDD0922F0E Q33663063-1611425D-C846-4315-AF30-D49314294B02 Q33713903-845EACE5-A719-4A1C-8B85-B0F84050F994 Q33730451-153E5F6C-2AAF-40BD-B94E-EF1896B9EE76 Q33874652-FF6897D0-310F-4FE0-AF17-CE37C38B3A76 Q33945680-521533FD-F945-46EA-8663-956E225A6453 Q33954953-4BAC5541-71CE-48A6-8264-8A95F19C3CBF Q34085930-52CD5419-39E8-4B8E-8331-B32C538AA33A Q34128906-AC6108FB-F127-42F1-819D-A222A4F5155C Q34206875-BC1810E7-081F-4445-8982-ACDD8BF13DD9 Q34330250-2866C1D1-8558-4073-9707-EFDC6C54E465 Q34443707-3417E99A-DB3E-4388-8087-E5F5A1432D13 Q34472125-2C033365-B48D-4301-BF9D-4F652266DAB7 Q34539879-F4EDD7C7-D655-4A00-AF37-FC531E2C8042 Q34539903-DE88B0A7-7C78-4E24-A085-8C86FA04B25F Q34576498-9FD0D02F-A72A-464E-A964-60269E69AA1B Q34633466-4116FFEF-2B95-4362-AA15-EBB3411EB3D6 Q34767725-D848B68F-8AA5-49F0-BFC5-3BE3ADAEDCBE Q35005484-4D4DDE82-9636-46D7-8EB3-20C4FF4ED558 Q35009241-2627F8A2-3F4B-4924-B782-ABD7497F1452 Q35069876-7179B043-F433-40E6-833C-66A802483B20 Q35096745-D0C8D260-32B1-4099-A207-407FDDC56796 Q35149637-AC931D6F-7C23-4481-8C81-DF1A22F28A10 Q35220399-80907A99-DC05-4EC6-B4A1-D8181BA09FC6 Q35285735-298C2216-5EA2-4EA1-95B0-9D9BA8CD07DA Q35496414-57152727-FF33-424C-BC1F-35D767B39BF4 Q35688529-76F55EBF-3C8E-4AA2-A1D2-598ED3115F55 Q35899079-0817BA56-887D-4EC7-BA0E-883BBE190F3A Q35990046-CFD74653-791F-46F3-9071-D535885073FA Q36060263-11BB049D-983E-4D82-A706-74F14EFAA303 Q36119591-E1E6125F-B601-4F9B-9234-E739C9504324 Q36191163-13EDC3A2-5682-4A0E-9550-BF610F28D391 Q36193546-F37370BC-6D97-4DA4-8007-AD142394A72E

P2860

Engineered lentivector targeting of dendritic cells for in vivo immunization.

http://www.wikidata.org/entity/Q36629181

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@ast

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@en

type

label

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@ast

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@en

prefLabel

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@ast

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@en

P1433

Q36629181-DB97996C-6229-405B-B91E-EAF303837A8F

P1476

Q36629181-53CE175F-DE71-4747-8EDD-C6FE0E8DEC48

P2093

Q36629181-22F7FA04-4FAC-4A5A-A757-CD3E60F99436

Q36629181-31ECFE8E-3BA9-4C2C-8C9E-319D78AE6BFA

Q36629181-5E8D7B12-AAF5-4226-BBD1-6078F24E8B90

Q36629181-60D9FF30-E518-4186-9E48-AD33FBCA7354

Q36629181-78DFF306-D56F-4DFE-871F-60ED2DD21E93

Q36629181-9ADC0E07-C58D-426B-B31F-BEB1D2627C7E

Q36629181-B0B9373D-2BF3-4607-A8D8-0EBB1B60DA2B

Q36629181-B32F5625-0120-48D3-808B-4CB979B40AC9

Q36629181-D4B171C9-C20D-43D5-938E-6AFDB49D326B

Q36629181-D792FDB6-5777-42AB-8CDD-CDF68B5F734C

P2860

Q36629181-078F55D4-2F5D-41A9-96F1-59C34F0FA73E

Q36629181-0F2C0A76-5DBB-4AA8-8777-18CAF425BDEF

Q36629181-1F3A9792-E9E1-41BC-B5D6-D86CA915F1F0

Q36629181-29B665FF-51B7-46F4-A157-51A90B5C0AF6

Q36629181-2A7FC06F-3A87-412F-A290-6D1280D2835F

Q36629181-307E1010-B15C-424E-89B1-BD776345A216

Q36629181-3B98D50B-0709-47C4-8895-1B62B86385EC

Q36629181-4845966E-7DA7-4202-86AE-749A35E59764

Q36629181-57F8E900-96B9-4C55-B12F-466DCBCBEB66

Q36629181-583F367F-F773-4468-B1DF-8A2CEE700352

P2888

Q36629181-4AA47A5F-83F2-492C-8016-E1ED6ABBE710

P304

Q36629181-02B043A0-A7C4-46A0-96A6-70E5EEDB1F60

P31

Q36629181-DA8F152A-7856-44C9-ABD7-5A9E0733269C

P356

Q36629181-199B9A9C-854D-46F9-A3AA-913132B01D55

P433

Q36629181-3CCF2B6C-E857-4BED-8251-B2324C6B7105

P478

Q36629181-D1C7EA21-80E8-42B4-BBD3-E5FE5DBEE5AE

P577

Q36629181-A2FDBAA0-19AA-416F-8143-394019AC7B96

P5875

Q36629181-40FCD42D-877C-4026-A348-DF33209083B1

P6179

Q36629181-6EC43DCF-C605-488A-9033-DEDC945EDC5F

P698

Q36629181-2E1B78EA-DA6F-4459-8FC3-5C1EB849517F

P921

Q36629181-1E92D666-8AF2-4F61-A64E-88843D3EA1CD

P932

Q36629181-81F39721-1983-4FBD-BF03-C981DFEC7A75

P356

P1433

Nature Biotechnology

P1476

Engineered lentivector targeting of dendritic cells for in vivo immunization.

@en

P2093

Abigail Elliot

http://www.w3.org/2001/XMLSchema#string

Anthony Walls

http://www.w3.org/2001/XMLSchema#string

David Baltimore

http://www.w3.org/2001/XMLSchema#string

Dongzi Yu

http://www.w3.org/2001/XMLSchema#string

Haiguang Yang

http://www.w3.org/2001/XMLSchema#string

Kendra Rideout

http://www.w3.org/2001/XMLSchema#string

Kye Il Joo

http://www.w3.org/2001/XMLSchema#string

Leslie Ziegler

http://www.w3.org/2001/XMLSchema#string

Lili Yang

http://www.w3.org/2001/XMLSchema#string

Pin Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer immunotherapy: moving beyond current vaccines

Binding of Sindbis virus to cell surface heparan sulfate

DC-SIGN and L-SIGN Can Act as Attachment Receptors for Alphaviruses and Distinguish between Mosquito Cell- and Mammalian Cell-Derived Viruses

Dendritic cells and the control of immunity

DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells

Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins

Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses

Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors

Tolerogenic dendritic cells

Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses.

P2888

P304

326-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT1390

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5555279

http://www.w3.org/2001/XMLSchema#string

P6179

1029715812

http://www.w3.org/2001/XMLSchema#string

P698

18297056

http://www.w3.org/2001/XMLSchema#string

P921

P932

2366162

http://www.w3.org/2001/XMLSchema#string